Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia

Overview

Journal Rev Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 30

PMID 39077515

Authors

Yohwan Lim

Seogsong Jeong

Myunghee Hong

Hyun Wook Han

Affiliations

Soon will be listed here.

Abstract

The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to increase to over half of the adult population by 2040 globally. Since the final diagnosis of NAFLD is made by a liver biopsy, several non-invasive approaches have been developed and validated to define NAFLD and evaluate NAFLD-associated diseases. Presently, NAFLD has been identified as an important and independent risk factor for developing several extrahepatic diseases, including atherosclerosis, cardiovascular disease (CVD), diabetes, and dementia. This review discusses current findings of up-to-date literature regarding the effects of NAFLD on the risk of atherosclerosis and CVD in Asia along with potential underlying biological mechanisms and therapeutic approaches to lower the NAFLD-related CVD risk. We further focus on the difference between NAFLD and metabolic dysfunction-associated fatty liver disease (MAFLD) on the risk of CVD and its implication by comparing the risk of NAFLD and MAFLD.

References

Huang Q, Zou X, Wen X, Zhou X, Ji L . NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?-Results From NHANES III. Front Med (Lausanne). 2021; 8:693507. PMC: 8280321. DOI: 10.3389/fmed.2021.693507. View

Katsiki N, Mikhailidis D, Mantzoros C . Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism. 2016; 65(8):1109-23. DOI: 10.1016/j.metabol.2016.05.003. View

Elsaid M, Li Y, Bridges J, Brock G, Minacapelli C, Rustgi V . Association of Bariatric Surgery With Cardiovascular Outcomes in Adults With Severe Obesity and Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2022; 5(10):e2235003. PMC: 9547320. DOI: 10.1001/jamanetworkopen.2022.35003. View

Kim K, Roh J, Lee S, Yoon J . Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease. Sci Rep. 2021; 11(1):2884. PMC: 7858633. DOI: 10.1038/s41598-021-81959-1. View

Podszun M, Chung J, Ylaya K, Kleiner D, Hewitt S, Rotman Y . 4-HNE Immunohistochemistry and Image Analysis for Detection of Lipid Peroxidation in Human Liver Samples Using Vitamin E Treatment in NAFLD as a Proof of Concept. J Histochem Cytochem. 2020; 68(9):635-643. PMC: 7649917. DOI: 10.1369/0022155420946402. View

Lee J, Kim D, Kim H, Lee C, Yang J, Kim W . Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2009; 42(7):503-8. DOI: 10.1016/j.dld.2009.08.002. View

Wong V, Chan W, Chitturi S, Chawla Y, Dan Y, Duseja A . Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2017; 33(1):70-85. DOI: 10.1111/jgh.13857. View

Mendez-Sanchez N, Bugianesi E, Gish R, Lammert F, Tilg H, Nguyen M . Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022; 7(5):388-390. DOI: 10.1016/S2468-1253(22)00062-0. View

Puri P, Mirshahi F, Cheung O, Natarajan R, Maher J, Kellum J . Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2007; 134(2):568-76. DOI: 10.1053/j.gastro.2007.10.039. View

10.

Slomko J, Zalewska M, Niemiro W, Kujawski S, Slupski M, Januszko-Giergielewicz B . Evidence-Based Aerobic Exercise Training in Metabolic-Associated Fatty Liver Disease: Systematic Review with Meta-Analysis. J Clin Med. 2021; 10(8). PMC: 8069623. DOI: 10.3390/jcm10081659. View

11.

Ciardullo S, Monti T, Sala I, Grassi G, Mancia G, Perseghin G . Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories. Hypertension. 2020; 76(2):562-568. DOI: 10.1161/HYPERTENSIONAHA.120.15220. View

12.

Li Y, Xu H, Wu W, Ye J, Fang D, Shi D . Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Oncotarget. 2018; 9(35):24155-24167. PMC: 5963622. DOI: 10.18632/oncotarget.23816. View

13.

Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T . Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021; 56(11):1022-1032. PMC: 8531127. DOI: 10.1007/s00535-021-01828-6. View

14.

Wen W, Li H, Wang C, Chen C, Tang J, Zhou M . Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis. Front Endocrinol (Lausanne). 2022; 13:934225. PMC: 9523252. DOI: 10.3389/fendo.2022.934225. View

15.

Jeong S, Oh Y, Choi S, Chang J, Kim S, Son J . Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults. Clin Mol Hepatol. 2022; 28(3):510-521. PMC: 9293607. DOI: 10.3350/cmh.2021.0332. View

16.

Weber C, Noels H . Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011; 17(11):1410-22. DOI: 10.1038/nm.2538. View

17.

Lee K, Wu P, Lin H . Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol. 2022; 29(1):77-98. PMC: 9845678. DOI: 10.3350/cmh.2022.0237. View

18.

Tariq S, Sidhu M, Toth P, Boden W . HDL hypothesis: where do we stand now?. Curr Atheroscler Rep. 2014; 16(4):398. DOI: 10.1007/s11883-014-0398-0. View

19.

Yi X, Liu Y, Zhou X, Wang Y, Deng J, Liu J . The Influence of Abdominal and Ectopic Fat Accumulation on Carotid Intima-Media Thickness: A Chongqing Study. J Stroke Cerebrovasc Dis. 2018; 27(7):1992-1997. DOI: 10.1016/j.jstrokecerebrovasdis.2018.02.052. View

20.

Thakur M, Sharma S, Kumar A, Bhatt S, Luthra K, Guleria R . Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis. 2012; 223(2):507-11. DOI: 10.1016/j.atherosclerosis.2012.06.005. View